Pain points
Why people look for OpenEvidence alternatives
Not available in the EU or UK — OpenEvidence has officially withdrawn from both markets, citing the EU Artificial Intelligence Act and regulatory uncertainty around AI systems (per OpenEvidence's own homepage notice, 2026). Clinicians practising in the EU or UK cannot register or use the platform, regardless of credentials.
Funded by pharmaceutical and medical-device advertising — OpenEvidence's own published advertising policy describes that sponsored summaries from pharma manufacturers may appear alongside answers (per openevidence.com/policies/advertising)
Accuracy on hard cases — a peer-reviewed medRxiv 2025 pilot study found 34% accuracy for standard OpenEvidence and 41% for Deep Consult on 100 subspecialty board questions; the leading frontier LLM scored 46% on the same benchmark
Repeatability concerns — the same study reported 77% (OE) / 72% (DC) same-question concordance, meaning roughly 1 in 4 questions returned a different answer between runs
US-centric verification — primary signup path requires a US National Provider Identifier (NPI); independent reviews report international clinicians often cannot complete the verification flow for Pro features
US-centric content — tends to cite American Heart Association guidelines and FDA approvals where UK clinicians would expect NICE recommendations and the British National Formulary, sometimes recommending drugs not licensed in the UK or EU
Single-purpose tool — no email integration, no private knowledge bases, no voice transcription, no multi-model choice; clinicians still need separate tools for the rest of their workflow
Never says 'I don't know' — the medRxiv authors documented that both modes can return answers not in the listed multiple-choice options without flagging uncertainty
The Comparison
Best OpenEvidence alternatives in 2026
Wysor
Free – €29.99/mo
AI workspace for clinicians with medical search across PubMed, FDA, FAERS, RxNorm, EMA, and ATC; multi-model chat (GPT-5, Claude, Gemini, DeepSeek); private knowledge bases; Gmail/Outlook integration; on-device voice transcription. Subscription-funded with no pharmaceutical advertising. Open to anyone — no NPI verification.
Strengths
- No pharmaceutical advertising — funded entirely by user subscriptions, no sponsored content alongside clinical answers
- Multi-model — switch between GPT-5, Claude, Gemini, and DeepSeek within one conversation; compare answers across models on the same question
- Structured medical data sources — 40M+ PubMed records with MeSH filtering, retraction detection, and citation-based reranking; 256K FDA drug labels and 20M FAERS adverse event reports; RxNorm drug resolution; EMA and ATC for international regulatory data
- Private knowledge bases — upload hospital protocols, departmental guidelines, internal SOPs; the agent cites from your private corpus alongside published literature
- Email integration for Gmail and Outlook — draft referrals, patient summaries, colleague emails in the same workspace where you do research
- On-device voice transcription — dictate consult notes; audio never leaves the device
- Open to anyone — no NPI verification, no clinician gating; available to physicians, residents, students, pharmacists, researchers, and life-sciences teams worldwide
- Transparent pricing — Free, €19.99/mo, or €29.99/mo. No demo required, no enterprise contract
- Contractual DPAs with every model provider — no training on your queries, no data retention beyond technical minimum
- Includes legal research tools (86M+ documents across 12 jurisdictions) and broader productivity features for multidisciplinary practices
Limitations
- Does not have full-text partnerships with NEJM, JAMA, Cochrane, NCCN, or Elsevier ClinicalKey AI — Wysor searches PubMed abstracts and surfaces citation context, but not the full body text under publisher licence
- No human-authored, peer-reviewed chapters in the UpToDate or DynaMed sense — Wysor surfaces primary literature and structured drug data, not editorialised summaries
- Newer platform with smaller clinician user base than the established incumbents
UpToDate (Expert AI)
Individual and institutional pricing on request from Wolters Kluwer
Wolters Kluwer's clinical reference product. Chapters are written and peer-reviewed by named physician authors and editors. Added AI-Enhanced Search in 2025 and UpToDate Expert AI as a generative AI layer over the existing chapter content, available in their Pro Plus tier.
Strengths
- Chapters are human-authored and peer-reviewed by named physicians
- AI generates from a closed, editorialised content set rather than the open web
- Established institutional licences in many hospitals; clinicians may already have access via their employer
Limitations
- Premium pricing relative to other reference tools — individual physician subscriptions and institutional Pro Plus plans require contacting Wolters Kluwer for current pricing
- Closed corpus by design — the AI synthesises only over UpToDate's own chapters and does not search PubMed or other primary literature directly; this is a deliberate editorial choice with both upsides (predictability) and trade-offs (narrower scope than open-corpus search engines)
- Per-seat licensing model is best suited to institutional procurement; individual or small-team adoption is more expensive per user than free or subscription alternatives
- Editorial focus reflects the specialties where UpToDate's author community is strongest — primarily internal medicine and US-board-aligned specialties; coverage is broad but depth varies by topic
DynaMed (DynaMedex)
Approximately $399/year individual reported by third parties; institutional pricing on request
EBSCO's evidence-based clinical reference tool. Uses a structured methodology with explicit evidence grading on recommendations. DynaMedex bundles DynaMed with Micromedex drug information.
Strengths
- Explicit evidence grading on recommendations
- DynaMedex bundles Micromedex drug information in the same product
- Mobile app and EHR integration available
Limitations
- Per-seat institutional licensing; pricing is best evaluated against your team size
- Topic coverage varies by subspecialty
- Generative AI features are less developed than dedicated AI-first tools
- Single-purpose reference — does not provide email, knowledge base, voice transcription, or multi-model chat
ClinicalKey AI
14-day free trial; pricing on request (US/Canada only)
Elsevier's generative AI clinical decision support tool, drawing on Elsevier's content library and partner content. Includes voice-to-text dictation and adult/pediatric context toggling.
Strengths
- Generative AI grounded in Elsevier-published and partner journal content
- Voice-to-text dictation in the mobile app
- 14-day free trial available
Limitations
- Available for purchase in the United States and Canada only — clinicians elsewhere cannot subscribe directly (per Elsevier's own subscription page, as of early 2026)
- Individual pricing not publicly listed — requires contacting Elsevier for current rates
- Single-purpose tool — does not provide email, knowledge base, or multi-model chat
- Closed publisher-curated corpus rather than open literature search
Vera Health
Free for verified clinicians; enterprise pricing on request
A newer clinical AI search tool launched in 2024. Combines literature search across a large open corpus with a drug database and a set of medical calculators. Free for verified clinicians and trainees in available regions.
Strengths
- Free tier for verified clinicians and trainees
- Open-corpus literature search approach rather than a closed editorialised chapter set
- Includes a drug database with dosing/interaction checks and a set of medical calculators in the same product
- Mobile apps for iOS and Android
Limitations
- Newer entrant — limited independent evaluation, no published peer-reviewed accuracy benchmarks comparable to those available for OpenEvidence
- Enterprise features (full EHR integration, formal SOC 2 documentation) require custom engagement and IT coordination
- Verification process, international availability, and long-term roadmap less documented than for established incumbents
- Like other free clinician-facing tools, the long-term funding model and how it may evolve over time is worth diligencing for institutional adoption
- Single-purpose tool — no email, knowledge base, voice transcription, or multi-model chat
Heidi Evidence
Free tier; paid tier reported at approximately $150/user/month
Heidi Health is an AI scribe with a recent clinical decision support add-on (Heidi Evidence, launched 2026) that draws on UK and Commonwealth clinical sources. Bundled into the same product as the scribe.
Strengths
- Clinical evidence sourced from UK and Commonwealth content lanes rather than US-only defaults
- Free tier available for the AI scribe
Limitations
- Heidi Evidence is recent (launched 2026) and has limited independent evaluation
- Primary product is the AI scribe; clinical evidence lookup is a secondary add-on
- Paid tier reported at approximately $150/user/month annually (per third-party reviews; verify current pricing on Heidi's site) — among the higher per-user prices in this list
- Single-purpose tool oriented toward consult documentation; does not provide knowledge bases, email integration, or multi-model chat
Our take
Why Wysor is the best OpenEvidence alternative
Wysor is an AI workspace built for clinicians who want more than literature search. It includes a medical research tool that pulls from PubMed (40M+ records with MeSH filters and citation reranking), FDA drug labels, FAERS adverse event reports, RxNorm, EMA, and ATC — alongside multi-model chat (GPT-5, Claude, Gemini, DeepSeek), private knowledge bases for your own protocols, Gmail and Outlook integration, and on-device voice transcription. Subscription-funded, no pharmaceutical advertising, no NPI verification gate, no per-seat enterprise contract. Free tier with 5 models and 1 knowledge base; €19.99/mo for Plus; €29.99/mo for Premium. Built by AI experts in Germany.
Try Wysor FreeImportant update: OpenEvidence is no longer available in the EU or UK
As of 2026, OpenEvidence has officially withdrawn from both the European Union and the United Kingdom. Their own homepage now displays a notice to visitors from those regions stating that OpenEvidence is not available there, citing the EU Artificial Intelligence Act and broader regulatory uncertainty around AI systems.
If you are a clinician practising in the EU or the UK, you cannot use OpenEvidence regardless of credentials, and you need a replacement. The alternatives listed below all serve EU and UK clinicians (with regional caveats noted in each entry).
Why clinicians look for OpenEvidence alternatives
For US clinicians who can still access OpenEvidence, it is the most widely used medical AI app among verified clinicians and has built genuinely impressive content partnerships — full-text access to NEJM, the JAMA Network, Cochrane Systematic Reviews, NCCN guidelines, and Elsevier's ClinicalKey AI. For a US physician with a National Provider Identifier (NPI) who wants a fast, well-sourced answer between patients, it works.
But several issues are pushing clinicians to compare alternatives, even where the platform is available.
First, the business model. OpenEvidence is free for verified US clinicians because it is funded by pharmaceutical and medical-device advertising. The company's own published advertising policy describes that sponsored summaries from pharmaceutical manufacturers may appear alongside clinical answers. OpenEvidence states it maintains a separation between ads and content, and that advertisers cannot influence what the system retrieves. This is a self-policed editorial boundary. For some clinicians, this is fine; for others, it is a category of question they would prefer not to manage on top of their actual clinical reasoning.
Second, the accuracy data. Independent peer-reviewed evaluations have produced sobering results. A 2025 medRxiv pilot study tested OpenEvidence and Deep Consult on 100 subspecialty board questions from the MedXpertQA dataset. Standard OpenEvidence scored 34%; Deep Consult scored 41%. The leading frontier LLM (GPT-o1, per Zuo et al.) scored 46% on the same benchmark. Same-question repeatability was 77% for OpenEvidence and 72% for Deep Consult — meaning roughly one question in four returned a different answer when re-run. An earlier study (Low et al.) found that OpenEvidence produced relevant answers for only 24% of open-ended clinical questions, while a competitor (ChatRWD) scored 58% on the same set.
Third, the access model. Even before the 2026 EU/UK withdrawal, primary verification was built around the US NPI. The underlying content is US-centric — citing American Heart Association guidelines and FDA approvals where a UK clinician would expect NICE and the British National Formulary, and sometimes recommending drugs not licensed in the EU. The 2026 withdrawal made this a moot point for European clinicians, but it remains relevant for any US clinician working internationally or with non-US patients.
This page compares six alternatives. Each has a different trade-off — peer-reviewed editorial rigour, evidence grading, premium-journal access, broad corpus coverage, regional fit, or workspace breadth. Pick the one whose trade-off matches your practice.
How to choose
The right tool depends on what you actually need from clinical AI. The single-purpose reference tools (UpToDate, DynaMed, ClinicalKey AI) cover one use case well: literature lookup with editorial review. The single-purpose AI search tools (Vera Health, Heidi Evidence) cover a similar use case with newer technology and looser editorial control. None of them include the email, knowledge-base, voice, or multi-model capabilities that most clinicians end up wanting alongside literature search — which is the gap Wysor fills.
If your only clinical-AI need is literature lookup and your hospital already provides an institutional licence, your existing reference tool (UpToDate, DynaMed, or ClinicalKey AI depending on what your institution chose) is probably enough.
If you are a clinician practising in the EU or the UK — where OpenEvidence is no longer available — you need a replacement that works in your region. Of the tools listed here, Wysor and Heidi are both available in the EU and UK; the publisher reference tools (UpToDate, DynaMed, ClinicalKey AI) depend on regional licensing.
If your needs go beyond literature search — multi-model AI chat, private knowledge bases for your own protocols and guidelines, email and voice integration, structured drug and regulatory data, no per-seat enterprise contract — Wysor is built for that. None of the other tools listed here cover this scope.
Sources
The accuracy and business-model claims about OpenEvidence on this page are drawn from the following published sources:
- "The accuracy and repeatability of OpenEvidence on complex medical subspecialty scenarios: a pilot study." Two-author pilot, medRxiv preprint, 2025.
- Zuo et al. "MedXpertQA: a benchmark for evaluating medical reasoning in LLMs." 2025.
- Low et al. "Answering real-world clinical questions using large language model, retrieval-augmented generation, and agentic systems." 2025.
- OpenEvidence published advertising policy: openevidence.com/policies/advertising
- Independent UK clinician review series, iatroX, 2025.
UpToDate, DynaMed, ClinicalKey AI, Vera Health, and Heidi pricing and feature claims are drawn from each vendor's published product pages, press releases, and independent reviews (Clinical AI Report, KLAS, Wolters Kluwer, EBSCO, Elsevier, Heidi Health, iatroX) accessed in 2026.
Ready to switch from OpenEvidence?
Get access to all major AI models with real privacy guarantees. Free to start, no credit card required.
Try Wysor FreeEditorial note: This page was created by the Wysor team. All feature and pricing information reflects publicly available data as of April 2026. Features, pricing, and policies may have changed since publication. We recommend verifying details on each tool's official website before making a decision.
Keep exploring
